Ma Jin, Zhu Shumin, Liu Zining, Mao Yafei, Li Xinyuan, Dai Lili, Zhao Xiaojie, Wei Congzhen, Liu Jinfeng, Geng Yulan
Laboratory, The Third Hospital of Hebei Medical University, Shijiazhuang 050051, Hebei Province, China.
Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang 050030, Hebei Province, China.
Evid Based Complement Alternat Med. 2022 Aug 9;2022:4641600. doi: 10.1155/2022/4641600. eCollection 2022.
To investigate the clinical value of interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor (TNF-), and interferon- (IFN-) in diagnosis and severity assessment of lung cancer.
In this observational study, 50 physical examination healthy subjects were included in the control group and 100 lung cancer patients were included in the study group. In the study group, 53 cases with pleural effusion were subgrouped to the pleural effusion group ( = 53), while 47 patients were assigned to the nonpleural effusion group ( = 47). Plasma cytokines IL-2, IL-4, IL-6, IL-10, TNF-, IFN-, and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores of all eligible subjects were collected and compared.
The study group showed significantly higher levels of plasma cytokines IL-2, IL-4, IL-6, IL-10, TNF-, and IFN- versus healthy subjects ( < 0.05). Deterioration of lung cancer was associated with increased plasma cytokine levels and APACHE II scores. The combination assay of the above plasma cytokines showed significantly better diagnostic efficacy for lung cancer versus the single assay of the cytokines. Dead patients had higher plasma cytokine levels versus survived patients. The accuracy of plasma IL-2, IL-4, IL-6, IL-10, TNF-, and IFN- levels in the severity assessment of lung cancer was comparable with that of the APACHE II scale.
The plasma cytokines IL-2, IL-4, IL-6, IL-10, TNF-, and IFN- are effective markers for the diagnosis of lung cancer. The combined assay contributes to the early diagnosis of lung cancer patients, and the persistent elevation of cytokines suggests an increased risk of death in lung cancer patients, so the detection of cytokine levels facilitates the severity assessment of lung cancer.
探讨白细胞介素2（IL-2）、白细胞介素4（IL-4）、白细胞介素6（IL-6）、白细胞介素10（IL-10）、肿瘤坏死因子α（TNF-α）和干扰素γ（IFN-γ）在肺癌诊断及病情严重程度评估中的临床价值。
在这项观察性研究中，对照组纳入50名健康体检者，研究组纳入100例肺癌患者。研究组中，53例有胸腔积液的患者被分入胸腔积液组（n = 53），47例患者被分入无胸腔积液组（n = 47）。收集并比较所有符合条件受试者的血浆细胞因子IL-2、IL-4、IL-6、IL-10、TNF-α、IFN-γ以及急性生理与慢性健康状况评分系统II（APACHE II）评分。
研究组血浆细胞因子IL-2、IL-4、IL-6、IL-10、TNF-α和IFN-γ水平显著高于健康受试者（P < 0.05）。肺癌病情恶化与血浆细胞因子水平及APACHE II评分升高有关。上述血浆细胞因子联合检测对肺癌的诊断效能显著优于单一细胞因子检测。死亡患者的血浆细胞因子水平高于存活患者。血浆IL-2、IL-4、IL-6、IL-10、TNF-α和IFN-γ水平在肺癌病情严重程度评估中的准确性与APACHE II量表相当。
血浆细胞因子IL-2、IL-4、IL-6、IL-10、TNF-α和IFN-γ是肺癌诊断的有效标志物。联合检测有助于肺癌患者的早期诊断，细胞因子持续升高提示肺癌患者死亡风险增加，因此检测细胞因子水平有助于肺癌病情严重程度的评估。
